Pivekimab Sunirine clinical trials
Pivekimab Sunirine is named as an intervention in 2 current clinical trials in our USA, France, South Korea, Taiwan, UK, Italy, Australia, China, Spain, Austria and Israel registers. 2 are recruiting patients now. The most common phase is Phase 1. The lead sponsor is AbbVie. The most-studied condition is Acute Myeloid Leukemia. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Where Pivekimab Sunirine is approved
All regulators →Of the three regulators tracked here, the first to approve Pivekimab Sunirine was the US, on 27 May 2026.
- 1 EU orphan designation, most recently for treatment of blastic plasmacytoid dendritic cell neoplasm (26 Jun 2020, positive)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
How Pivekimab Sunirine works
All drug targets →- Interleukin-3 receptor subunit alpha binding agent Binding agentTarget: Interleukin-3 receptor subunit alpha✓ In ChEMBL and the Guide to Pharmacology
- Acute myeloid leukemiaPhase 2/3
- B-cell acute lymphoblastic leukemiaPhase 1/2
- CD4+/CD56+ hematodermic neoplasmPhase 1/2
- T-cell acute lymphoblastic leukemiaPhase 1/2
- Mixed phenotype acute leukemiaPhase 1/2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4297991, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 14543, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Pivekimab Sunirine
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Pivekimab Sunirine
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
NCT07581002 · Acute Myeloid Leukemia
|
Phase 2/3 | Recruiting | AbbVie | USA, China, France, Spain, Austria, South Korea, Taiwan, Israel |
|
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
NCT07306832 · Acute Myeloid Leukemia
|
Phase 1 | Recruiting | AbbVie | UK, USA, France, Italy, South Korea, Taiwan, Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Pivekimab Sunirine in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Pivekimab Sunirine. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A Phase 1b Study of the Safety and Pharmacokinetics of Pivekimab Sunirine in Pediatric Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML).
2024-520125-36-00 · CTIS ↗ · Neoplasms
|
Phase 1 | Ongoing | AbbVie Deutschland GmbH & Co. KG | Spain, Hungary, Czechia + 3 more |
Conditions studied with Pivekimab Sunirine
1 conditionSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| AbbVie | 2 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Pivekimab Sunirine trials
How many clinical trials are testing Pivekimab Sunirine?
2 current trials in our USA, France, South Korea, Taiwan, UK, Italy, Australia, China, Spain, Austria and Israel registers name Pivekimab Sunirine as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Pivekimab Sunirine trials recruiting patients?
Yes. 2 of the 2 trials are recruiting: 2 with sites in USA, 2 with sites in France, 2 with sites in South Korea, 2 with sites in Taiwan, 1 with sites in UK, 1 with sites in Italy, 1 with sites in Australia, 1 with sites in China, 1 with sites in Spain, 1 with sites in Austria and 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Pivekimab Sunirine clinical trials?
The lead sponsor is AbbVie. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Pivekimab Sunirine works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Pivekimab Sunirine works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Pivekimab Sunirine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.